跳至主要内容
临床试验/CTRI/2020/01/022785
CTRI/2020/01/022785尚未招募2 期

An Open Label, Single Arm Clinical study To Evaluate The Safety and Efficacy of HPLT031707 SYRUP in Cases of Thrombocytopenia Associated With Dengue Fever in Pediatric Population - PL_S

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)Both male and female pediatric subjects between the age group between >=2 years to <=12 years
  • 2)Pediatric subjects already confirmed to have DF (Dengue Fever) through ELISA based NS1 Antigen test and/or IgM.
  • 3)Pediatric subjects who have been clinically diagnosed with dengue fever associated with thrombocytopenia vis a vis platelet count between 50000 cells/mm3 to 1,00,000 cells/mm3.
  • 4)Pediatric subjects with the SGPT level not more than twice the upper limit of the normal
  • 5)Parents/Guardians/Caregiver related to pediatric subject willing to give written informed consent for his/her participation to the study
  • 6)Pediatric subject aged > 7 years of age willing to sign the assent form for his/her participation in the study
  • 7)Pediatric subjects who have not participated in this kind of trial in the past 4 weeks

排除标准

  • 1)Pediatric subjects diagnosed with DHF Grade 3 or 4,with hypotension / hypovolemia and dehydration
  • 2)Pediatric subjects with platelet count < 50000 cells/mm3
  • 3)Pediatric subjects weighing <10 Kgs and >45 Kgs
  • 4)Pediatric subjects with any febrile condition with temperature >=103 degree ofF and with a history of any febrile seizures.
  • 5)Pediatric subjects presenting with hemorrhagic phenomena at Day 1 (screening/baseline) evidenced with petechiae, ecchymoses, or purpura, bleeding from the oral mucosa, gastrointestinal tract (hemetemesis or melaena.), injection sites or other locations.
  • 7)Pediatric subjects with the history of juvenile diabetes mellitus treated with medication.
  • 8)Pediatric subjects with the history of clinically significant cardiovascular condition treated with medication
  • 9)Pediatric subjects with history of UTI or acute or chronic infectious condition and on any antibiotics like polymyxin B, rifampicin, amikacin, nalidixic acid, gentamycin, cholarmphenicol, oflaxacin
  • 10)Pediatric subjects with a history of established hematological disorders including idiopathic thrombocytopenia purpura, leukemia, hemophilia
  • 11)Pediatric subjects who have received blood products or blood/platelet transfusion during the current hospital stay or during last one month
  • 12)Pediatric subjects who are hypersensitive to any of the ingredients of the study medication
  • 13)Pediatric subjects with a history of clinically significant systemic condition treated with aspirin or corticosteroids or heparin

研究者

相似试验